A phase II study evaluated the effect of pembrolizumab (NCT01876511) in colorectal cancer with deficiency of DNA mismatch repair (MMR) ability (dMMR), those with functional MMR protein expression, and all solid tumors with dMMR. This evidence concerns the gene MRC1 and colorectal cancer.